Relief of dystonia symptoms is sustained in pediatric patients undergoing deep brain stimulation
News Jun 09, 2015
Children and adolescents who received deep brain stimulation for generalized dystonia maintained significant symptom relief for up to eight years, according to a study presented at the 12th World Congress of the International Neuromodulation Society (June 6-11, 2015).
The results reinforce the observation that patients with a shorter duration of symptoms, and a younger age at implantation, experience better outcomes, said Fabián Piedimonte, M.D., FIPP, of the Argentinean chapter of the International Neuromodulation Society – Sociedad Argentina de Neuromodulación (SANE), the CENIT Foundation, and Buenos Aires Provincial Program of Neuromodulation. The study is being presented as an oral abstract at the 12th World Congress by co-author and SANE President Juan Carlos Andreani, M.D., of the CENIT Foundation and Buenos Aires Provincial Program of Neuromodulation.
Dystonia is considered the third most-common movement disorder after essential tremor and Parkinson’s disease. Its symptoms include twisting and repetitive motions or abnormal posture, which can be frustrating and painful. While there are many types and causes, one of the most severe types of dystonia can begin in childhood and become severe before the end of the teen years.
Previous experience in Parkinson’s disease has suggested that if conservative measures do not adequately control dystonia symptoms, deep brain stimulation to the globus pallidus interna (Gpi) may be effective.
The study being reported today confirms growing evidence that deep brain stimulation to the Gpi is most effective in patients with primary dystonia (not secondary to some other condition or lesion), particularly in patients with primary dystonia who have a hereditary component, and carry the DYT1 mutation.
The 16 patients in the study were treated at medical centers in Buenos Aires. Their average age of onset was 9 years old (between 1 – 14 years of age); the median age at surgery was 12 years (between 8 – 19 years of age). On average, patients’ motor symptoms improved 69 percent and their disability sub-scores improved 60 percent. Some patients saw complete symptom relief. In four of the 16 patients, the motor-symptom improvement was less than 50 percent. Half of those patients did not carry the DYTI mutation.
The patients were seen every few months to adjust their stimulation parameters, since the natural evolution of the disease can cause new symptoms to develop. The pediatric patients were operated on under general anesthesia in a single-stage procedure, using microelectrode recordings to map the best path to guide the stimulation leads to the stimulation target structure. As rechargeable pulse generators became available, they were preferentially used to provide the therapeutic stimulation, since they do not require replacement surgery every few years.
n dystonia, initial symptom relief from deep brain stimulation appears in weeks, with settings being optimized over the first two or three months. The best relief generally develops during the first year post-surgery.
In addition to helping reduce patients’ symptoms, other important benefits of adequately managing dystonia include allowing the children’s bones to continue growth with less risk of deformity from ongoing muscle contraction, and enabling ease of hygiene through better voluntary movement.
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Synaptotagmin 7 Ensures Efficiency of Inhibitory Signal TransmissionNews
Researchers at IST Austria define function of an enigmatic synaptic protein, synaptotagmin 7.READ MORE
Molecules in Spit Could Help Diagnose ConcussionsNews
Diagnosing a concussion can sometimes be a guessing game, but clues taken from small molecules in saliva may be able to help diagnose and predict the duration of concussions in children, according to Penn State College of Medicine researchers.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE